Mounjaro 2.5mg — what the starting dose is really for

What the SURMOUNT trial tells us about the 2.5mg period

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes to tirzepatide or placebo over 72 weeks. Participants began at 2.5mg and stepped up through the licensed schedule. At the highest dose of 15mg, average body-weight reduction was around 20–21%, a figure that generated considerable attention when the results were published.

What the headline numbers do not tell you is that the 2.5mg phase produced relatively modest weight change on its own. That is by design. The dose titration schedule exists because GLP-1 and dual GIP/GLP-1 medicines carry a well-established gastrointestinal side-effect profile (nausea, loose stools, indigestion, and sometimes vomiting) that tends to be most pronounced when treatment starts or when a dose increases. Beginning at 2.5mg and holding for four weeks gives most people's systems time to adapt before the clinically active doses arrive.

The NHS medicines information for tirzepatide reflects this structure directly: 2.5mg is the starting strength, with the prescriber guiding each subsequent step. Understanding this context helps explain why some people report limited change in the first month and then notice a more pronounced effect as the dose increases over the following weeks.

Why 2.5mg is not simply a low version of the full treatment

A question that comes up frequently (the team at our clinical team hears it regularly) is whether staying at 2.5mg for longer than four weeks is sensible if it feels tolerable and gentle. The short answer from the clinical evidence: the 2.5mg dose was not studied as a long-term maintenance option. SURMOUNT-1 used it solely as a run-in, and NICE's appraisal of tirzepatide (TA1026, published December 2024) evaluates the medicine at therapeutic doses, not at starter-dose level. Remaining at 2.5mg indefinitely has no basis in the trial evidence for sustained weight management.

This matters practically. Some people feel minimal side effects at 2.5mg and wonder whether stepping up is necessary. Others feel noticeable nausea and worry about going higher. Both responses are normal, and both deserve a clinical conversation rather than a self-directed decision. Titration pace, how long to wait between steps, and whether to pause at a particular dose if side effects are difficult, these are exactly the judgements a prescriber is there to make. Details on the full titration pathway are covered in more depth on the overview of moving from 2.5mg to 5mg.

The pen itself is worth understanding too. A single Mounjaro 2.5mg KwikPen delivers four pre-set doses, one per week, which means one pen carries you through the entire starter month. There is no measuring or adjusting involved.

Side effects at 2.5mg: what the evidence suggests you might notice

Because 2.5mg is the gentlest point on the titration ladder, side effects tend to be milder here than at higher doses, though they are not absent. The most commonly reported effects across the SURMOUNT programme were gastrointestinal: nausea, constipation, diarrhoea, and burping featured most often. Injection-site reactions, fatigue, and mild headache were also recorded, typically resolving within days to a couple of weeks as the body adjusts.

The MHRA has emphasised that acute pancreatitis, while infrequent, is a recognised risk with GLP-1 class medicines. Severe stomach pain that spreads towards the back, with or without vomiting, warrants prompt medical assessment, do not wait for the next scheduled review. Reporting any unexpected or severe symptoms to your prescriber, or via the Yellow Card scheme, is always appropriate. That reporting channel exists for a reason, and patient reports contribute meaningfully to post-marketing safety data for newer medicines like Mounjaro, which still carries a Black Triangle (▼) status indicating enhanced MHRA monitoring.

For anyone planning ahead, if a bank holiday or a period away means a dose might fall awkwardly, raise that with your prescriber before it happens rather than after. The Patient Information Leaflet covers how to handle a missed dose; your prescriber's guidance always takes precedence over general advice.

Who the 2.5mg starting dose applies to, and where it sits in the bigger picture

The licensed UK indication for Mounjaro covers adults with a BMI of 30 or above, or a BMI of 27 and above alongside at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability; the prescriber considers the full clinical picture.

Private treatment removes the waiting-list barrier that NHS access currently involves for most people. The full Mounjaro overview covers NHS and private routes in detail, and if you are weighing up cost, the Mounjaro cost page explains what a legitimate private price includes, consultation, prescription, and clinical aftercare are all part of it, not optional extras. If you want a closer look at how the Mounjaro 2.5mg dose is structured and what to expect from it clinically, that detail is covered separately, including guidance on the 2.5ml Mounjaro injection volume and what that means in practice when you are using the pen. The 2.5mg starter period is the same regardless of route; the clinical framework around it is what differs.

If you are ready to find out whether Mounjaro is clinically appropriate for you, check your eligibility with our prescribers, the consultation is free, and a named clinician reviews every application the same day it arrives.